Bristol-Myers Squibb (NYSE: BMY ) is expected to report Q1 earnings on April 25. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bristol-Myers Squibb's revenues will compress -26.1% and EPS will contract -34.4%.
The average estimate for revenue is $3.88 billion. On the bottom line, the average EPS estimate is $0.42.
Last quarter, Bristol-Myers Squibb reported revenue of $4.19 billion. GAAP reported sales were 23% lower than the prior-year quarter's $5.45 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.47. GAAP EPS of $0.56 for Q4 were 12% higher than the prior-year quarter's $0.50 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 76.4%, 120 basis points better than the prior-year quarter. Operating margin was 21.5%, 840 basis points worse than the prior-year quarter. Net margin was 22.1%, 650 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $16.54 billion. The average EPS estimate is $1.83.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,677 members out of 1,793 rating the stock outperform, and 116 members rating it underperform. Among 505 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 488 give Bristol-Myers Squibb a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is hold, with an average price target of $34.53.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.